![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Fowler, Nathan Hale; Dickinson, Michael; Dreyling, Martin; Martinez-Lopez, Joaquin; Kolstad, Arne; Butler, Jason; Ghosh, Monalisa; Popplewell, Leslie; Chavez, Julio C.; Bachy, Emmanuel; Kato, Koji; Harigae, Hideo; Kersten, Marie Jose; Andreadis, Charalambos; Riedell, Peter A.; Ho, P. Joy; Perez-Simon, Jose Antonio; Chen, Andy I.; Nastoupil, Loretta J.; Tresckow, Bastian von; Ferreri, Andres Jose Maria; Teshima, Takanori; Patten, Piers E. M.; McGuirk, Joseph P.; Petzer, Andreas L.; Offner, Fritz; Viardot, Andreas; Zinzani, Pier Luigi; Malladi, Ram; Zia, Aiesha; Awasthi, Rakesh; Masood, Aisha; Anak, Oezlem; Schuster, Stephen J. und Thieblemont, Catherine
(2021):
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
In: Nature Medicine, Bd. 28, Nr. 2: S. 325-332
Morschhauser, Franck; Flinn, Ian W.; Advani, Ranjana; Sehn, Laurie H.; Diefenbach, Catherine; Kolibaba, Kathryn; Press, Oliver W.; Salles, Gilles; Tilly, Herve; Chen, Andy I.; Assouline, Sarit; Cheson, Bruce D.; Dreyling, Martin; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Surai; Cheng, Ji; Lu, Dan; Penuel, Elicia; Hirata, Jamie; Wenger, Michael; Chu, Yu-Waye und Sharman, Jeff
(2019):
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
In: Lancet Haematology, Bd. 6, Nr. 5, E254-E265